Post-ROE-P/B curve steepening strategy

Akihiro Murakami
Chief Quantitative Strategist, Japan
Nomura Securities Co., Ltd.
+81 (0)3 6703 1746
akihiro.murakami@nomura.com

May, 2013

See Appendix A-1 for analyst certification, important disclosures and the status of non-US analysts.

Any authors named on this report are research analysts unless otherwise indicated.
Summary

- Current investment environment in the Japanese equity market:
  - Japanese equity quant fund performance and representative factors
  - Who are buying Japanese stocks?

- Our investment strategy:
  (a) Major buyers of Japanese equities are nonresident investors
    - Strategy utilizing non-resident investors’ stock selection skills
  (b) Reliability of analyst forecasts improving
    - Earnings revisions focusing on the ROE-P/B curve
  (c) The BOJ continues to be a major buyer of ETFs
    - Contrarian to the passive fund trading
Who are buying Japanese stocks?

Trading by trust banks, insurance and nonresident investors

Note: Shows trust banks', insurance cos' and nonresident investors' (bottom graph) trading value, taken from equity purchases by investor category data (right axis) and TOPIX return(left axis). Sample period is January 2011 through 10.May.2013.

Source: Nomura, from TSE's equity trading value by investor category data
As part of monetary easing, the BOJ also keeps buying Japanese ETFs

BOJ’s ETF purchases and the TOPIX

Note: Shows the actual amount of ETFs purchased by BOJ (right axis) and TOPIX return(left axis). Sample period is January 2011 through 10 May 2013. Source: Nomura, based on BOJ and other data.
Japanese equity quant funds started to recover since the change of government

Average performance of Japanese equity quant funds

Note: Shows daily average return (Jensen's alpha), on an indexed basis, on 23 funds (domestic publicly offered investment trusts and nonresident investor funds) that invest in Japanese equities using a quant-based approach. Sample includes long-only, individual stock long-short, and market-neutral (long on individual stocks, short on index futures, for example) funds. Sample period is January 2011 through 10.May.2013.

Source: Nomura
Mimic portfolio’s performance of quant funds

Average performance of Mimic portfolio and Quant funds

Note: Shows daily return of mimic portfolio (the composite factor of E/P, B/P, Revision and reversal (past 3 month return)) and daily average return (Jensen’s alpha), on an indexed basis, on 23 funds (domestic publicly offered investment trusts and nonresident investor funds) that invest in Japanese equities using a quant-based approach. Sample includes long-only, individual stock long-short, and market-neutral (long on individual stocks, short on index futures, for example) funds. Sample period is January 2011 through 10 May 2013.

Source: Nomura
Value factors worked as the main driver for the Q4 quant recovery
But.....

Daily performance of E/P and B/P

Note: Universe of TOPIX500 stocks is divided into 5 quintiles, with an equal number of stocks in each quintile, by factor value. Portfolios are rebalanced at the beginning of each month.
Cumulative spread return (#5 – #1) is calculated on a daily basis (end-Dec. 2010 = 0). We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance. Sample period is 4 Jan. 2011 – 10 May 2013.

Source: Nomura
B/P factors were driven by credit risk factor

Factor performance for B/P and 5-year CDS spreads

Note: We divided the universe of TOPIX 500 stocks into five groups in terms of both B/P and 5-year CDS spreads at the beginning of each month. Figure shows cumulative monthly returns on a strategy of going long on the group of stocks with the highest factor values and short on the group of stocks with the lowest factor values, for each factor. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance. Sample period is January 2011 through 10 May 2013.

Source: Nomura
Credit risk factor may no longer be a driver for B/P factors

CDS spreads for high-B/P and low-B/P stocks

Note: Universe is TOPIX 500 stocks for which 5-year CDS spread data were available. We divided the universe into five groups on the basis of B/P factor values at the beginning of each month, and calculated the median 5-year CDS spread for the groups of stocks with the highest and lowest B/P, respectively. Sample period is January 2011 through May 2013.

Source: Nomura
We expect profit-based factors to emerge as the next main driver

Daily performance of ROE, revision and recurring profit growth

End-2010/12 = 0%

Cumulative return

Revision
ROE
Recurring profit growth

Great East Japan Earthquake
European financial crisis
Resurgence of European financial crisis
Abenomics-Driven Rally

Note: Universe of TOPIX500 stocks is divided into 5 quintiles, with an equal number of stocks in each quintile, by factor value. Portfolios are rebalanced at the beginning of each month. Cumulative spread return (#5 – #1) is calculated on a daily basis (end-Dec. 2010 = 0). Sample period is 4 Jan. 2011 – 10 May.2013. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance.

Source: Nomura
Nonresident investor purchases likely to work more positively for profit-based factors than value factors

Comparison of risk characteristics:
Stocks overweighted by domestic pension funds vs. Stocks overweighted by nonresident investors

Note: we calculated risk characteristics of each portfolio and plotted the historical average of each risk characteristic. We conducted a cross-sectional normalization of each set of data so that weighted average market cap was 0 and variance was 1 at the beginning of each month, adjusting standard deviation to ±3σ if it exceeded that level, and repeated this process three times.

Sample period is June 1995 through March 2013.

Source: Nomura
Idea 1: Learning from non-resident investors’ stock selection skills

Performance of stocks overweighted by domestic pension funds and nonresident investors

(End-1995/6 = 0%)

Cumulative return

Active weight factor of Nonresident investors

Active weight factor of Domestic Pension

ROE factor

Note: We divided the universe of TSE-1 stocks into five groups based on their active weightings in the portfolios of nonresident investors at the start of each month. Figure shows cumulative monthly returns on a strategy combining long positions on stocks in the highest group (overweighted stocks) with short positions on stocks in the lowest group (underweighted stocks). We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance. Sample period is June 1995 through April 2013.

Source: Nomura
Company valuation and profitability closely associated

- A simple residual income model gives the relationship between future ROE and P/B ratio.

\[ P_{i,t} = B_{i,t} + \sum_{j=1}^{\infty} \frac{ROE_{t+j} - r_E}{(1 + r_E)^j} B_{t+j-1} \]

The ROE-P/B curve: the cross sectional relationship between ROE and valuation (P/B)

Note: We plotted each stock's expected ROE (next-FY forecast where available, otherwise current-FY forecast) on the x-axis and its P/B on the y-axis, in a two-dimensional scatter plot. Universes were TSE-1 stocks as at the beginning of April 2013 and the beginning of January 2009, respectively. To remove outliers, we excluded stocks in the top 1% and bottom 1% of the universe in terms of ROE from our analysis.

Source: Nomura
The ROE-P/B curve fitted by converted model

Relationship between ROE and valuation (log P/B)

The converted model: 
\[ \ln \left( \frac{P_{i,t}}{B_{i,t}} \right) = \delta_t + \beta_t Z_{ROE_{i,t}} + \epsilon_{i,t} \]

Note: We plotted each stock's standardized expected ROE on the x-axis and its log P/B on the y-axis, in a two-dimensional scatter plot. Universe was TSE-1 stocks at the beginning of April 2013. We estimated the best fit line using model \( \ln \left( \frac{P_{i,t}}{B_{i,t}} \right) = \delta_t + \beta_t Z_{ROE_{i,t}} + \epsilon_{i,t} \), where \( \ln(*) \) is the natural log of *, \( \delta_t \) and \( \beta_t \) are the intercept and regression coefficient, respectively, at time \( t \), and \( \epsilon_{i,t} \) is the residual. To estimate the regression coefficient, we standardized ROE, the explanatory variable, so that the average was 0 and the standard deviation was 1, and rounded any values beyond \( \pm 3 \sigma \) to \( \pm 3 \sigma \). To remove outliers, we excluded stocks in the top 1% and bottom 1% of the universe in terms or ROE from our analysis.

Source: Nomura
The ROE-P/B curve has recently steepened rapidly

- The slope of the curve (β coefficient) has recovered to the level prior to Lehman collapse.

Time series β coefficient for ROE-P/B curve

The association between expected ROE and P/B is strong.

The association is weak.

Note: Universe was TSE-1 stocks. We carried out a cross-sectional regression analysis using expected ROE and P/B ratios at the beginning of each month, and the model

\[ \ln\left( \frac{P/B_i}{\bar{P}/\bar{B}} \right) = \delta_t + \beta_t \times \text{ROE}_{i,t} + \epsilon_{i,t}, \]

where \( \ln(*) \) is the natural log of *, \( \delta_t \) and \( \beta_t \) are the intercept and regression coefficient, respectively, at time \( t \), and \( \epsilon_{i,t} \) is the residual. Sample period was January 1987 through April 2013. To estimate the regression coefficient, we standardized ROE, the explanatory variable, so that the average was 0 and the standard deviation was 1, and rounded any values beyond ±3σ to ±3σ. To remove outliers, we excluded stocks in the top 1% and bottom 1% of the universe in terms of ROE from our analysis. We used a low-pass filter to determine phases of the coefficient.

Source: Nomura
What does the steepening of the curve indicate?

- We hypothesize that the slope of the curve indicates the effectiveness of revision strategy.

Schematic for phases when slope of ROE-P/B curve is high (steep) and low (flat)

Source: Nomura
Revision factors are certainly effective when the curve becomes steep

Effectiveness of revision factor when the curve is steep / flat

Note: Universe was TSE-1 stocks. We investigated the effectiveness of the earnings forecast revision factor in high, medium, and low phases of regression coefficient $\beta_i$, estimated using model

$$\ln \left( \frac{R_{it}}{\beta_i} \right) = \delta_i + \beta_i Z_i \cdot ROE_{it} + \epsilon_{it}.$$  

To calculate factor returns, we divided the universe into five groups based on the revision factor, then calculated statistical data for monthly returns on a strategy of going long on the top group and short on the bottom group. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance.

We divided the entire sample period into three groups based on coefficient value. We defined periods with coefficient values above the level that divides the top third from the middle third as high phases and periods with coefficient values below the level that divides the top third from the middle third as low phases.

Source: Nomura
In steep phase, profit-based factors perform well

Difference in factor performance between “Steep” and “Flat” phases

Note: Universe was TSE-1 stocks. We investigated the effectiveness of a key factors in high, medium, and low phases of regression coefficient \( \beta_t \), model (*) \( \ln \left( \frac{P_{t+1}}{B_{t+1}} \right) = \delta_t + \beta_t Z_{ROE_{t+1}} + \epsilon_{t+1} \). To calculate factor returns, we divided the universe into five groups in terms of each factor, and calculated statistical data for monthly returns on a strategy of going long on the top group and short on the bottom group for each factor (but long on the bottom group and short on the top group in the case of P/E and P/B). Figure shows difference between time series average/standard deviation (annualized) in high and low phases. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance. We divided the entire sample period into three groups based on coefficient value. We defined periods with coefficient values above the level that divides the top third from the middle third as high phases and periods with coefficient values below the level that divides the top third from the middle third as low phases.

Source: Nomura
The curve for high-ROE stocks has tended to steepen more than others

Relationship between ROE and valuation (log P/B) varies with level of ROE

$\beta$ coefficient of ROE-P/B curve for different levels of expected ROE

$y = 0.8278x - 0.2294$

Converted relationship between ROE and P/B (April 2013)

Note: We plotted each stock’s standardized expected ROE on the x-axis and its log P/B on the y-axis, in a two-dimensional scatter plot. Universe was TSE-1 stocks at the beginning of April 2013. We divided the universe into three groups in terms of expected ROE at the beginning of each month and estimated the best fit line for each group using model $\ln \left( \frac{P_i}{B_i} \right) = \delta_t + \beta_t \cdot \text{ROE}_t + \epsilon_{it}$, where $\ln(*)$ is the natural log of *, $\delta_t$ and $\beta_t$ are the intercept and regression coefficient, respectively, at time $t$, and $\epsilon_{it}$ is the residual. To estimate the regression coefficient, we standardized ROE, the explanatory variable, so that the average was 0 and the standard deviation was 1, and rounded any values beyond ±3σ to ±3σ. To remove outliers, we excluded stocks in the top 1% and bottom 1% of the universe in terms or ROE from our analysis.

Note: Universe was TSE-1 stocks. We divided the universe into three groups based on expected ROE at the beginning of each month, and carried out a regression analysis for each group using model $\ln \left( \frac{P_i}{B_i} \right) = \delta_t + \beta_t \cdot \text{ROE}_t + \epsilon_{it}$.

Shows time series data for regression coefficient $\beta_t$. Sample period was January 1987 through April 2013.

Source: Nomura
Idea 2: revision factor is most effective for the high-ROE group

Revision factor performance by expected ROE

(End-Dec 1986 = 0%) Cumulative return

High ROI
Medium ROI
Low ROI

Note: Universe was TSE-1 stocks. Sample period was January 1987 through 12 April 2013. We divided the universe into three groups based on expected ROE at the beginning of each month, divided these three groups into a further five groups each based on our earnings forecast revision factor, and calculated monthly returns on a strategy of going long on the top group and short on the bottom group in terms of the earnings forecast revision factor, for each ROE group. Figure shows cumulative monthly returns. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance.

Source: Nomura
Earnings revisions were larger (smaller) for the (low) high-ROE group

The absolute value of revisions factor by expected ROE

Note: Universe was TSE-1 stocks. Sample period was January 1987 through April 2013. We divided the universe into three groups based on expected ROE at the beginning of each month. Figure shows time series averages of the absolute value of the revision factor for each group.

Source: Nomura
Passive funds have shown growing presence in the Japanese equity market

- AUM for passive Japanese equity ETFs has grown remarkably and became double in the last 3 years.
- The BOJ is expected to keep buying Japanese stocks.

**AUM growth for passive Japanese equity ETFs**

[end-Jan.2005 = 1.0]

<table>
<thead>
<tr>
<th>Year</th>
<th>AUM growth</th>
<th>AUM growth – TOPIX return</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AUM growth: 67,044 mil USD

Note: Shows growth in AUM (assets under management) for passive ETFs (excluding leveraged and inverse ETFs) that track Japanese equities and are listed on major markets in the US and Asia, including Japan. The red line shows cumulative monthly growth in AUM from the beginning of 2005 (AUM at beginning of 2005 = 1). The blue line shows the cumulative spread between monthly AUM growth and monthly TOPIX return. Sample period is February 2005 through March 2013.

Source: Nomura
Jan, Apr, Jul and Oct are periodical index rebalance season
Anomalies might be seen around index events

- Typical trading pattern of TOPIX-tracking fund

- Trading in typical event-driven strategy

(a) Stocks about to see a relative increase in FFW → Buy
(b) Stocks about to see a relative decrease in FFW → Sell

Investments carried out in advance on basis of forecasts
(a) Stocks expected to see a relative increase in FFW → Long
(b) Stocks expected to see a relative decrease in FFW → Short

Reverse trades to lock in profits
Typical event-driven strategy

Investments carried out in advance on basis of forecasts

(a) Stocks expected to see a relative increase in FFW → Long
(b) Stocks expected to see a relative decrease in FFW → Short

Rebalance Date
Day before last business day
in Jan / Apr / Jul /Oct

Note: In this event, all constituent stocks, including stocks unchanged in FFW, see a change in their TOPIX weighting. We compare TOPIX weightings based on post FFW and new FFW. Covering periodic reviews of FFW in every October from 2006 through 2011. Sample size for each group is around 400 stocks. Average cumulative excess return relative to TOPIX from 20 trading days before announcement/date to 20 days after announcement/rebalance date. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance.

Source: Nomura
After the rebalances of passive funds, return reversal is expected

**Announcement Date**
5th business day in Jan / Apr / Jul / Oct

**Rebalance Date**
Day before last business day in Jan / Apr / Jul / Oct

Trading by passive funds

(a) Stocks about to see a relative increase in FFW → Buy
(b) Stocks about to see a relative decrease in FFW → Sell

Note: In this event, all constituent stocks, including stocks unchanged in FFW, see a change in their TOPIX weighting. We compare TOPIX weightings based on post FFW and new FFW. Covering periodic reviews of FFW in every October from 2006 through 2011. Sample size for each groups is around 400 stocks. Average cumulative excess return relative to TOPIX from 20 trading days before effective date to 20 days after announcement/rebalance date. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance.

Source: Nomura
Effect of FFW change on valuations

- B/P value spread of the stocks for which FFWs are increased and decreased is expanded more than 3%. Then, the spread is eliminated gradually.

(a) Stocks for which FFWs are to be increased (Buy) → relatively overvalued

(b) Stocks for which FFWs are to be decreased (Sell) → relatively undervalued

Note: Taking TSE-1 stocks as our universe, we calculated the average P/B of stocks for which the FFW (free-float weight) was increased or decreased, respectively, in the periodic FFW review for the TOPIX carried out in October each year from 2006 through 2011. We then calculated the spread between these two averages, respectively, and the average P/B for the universe (the value spread). We rebased the data so that the value spread in the month preceding the announcement of the October FFW review each year = 0%.

Source: Nomura
Idea 3: investment strategy based on change in FFW

- Start investment at the beginning of the next month when passive funds are rebalanced.
- Short the stocks for which FFWs increased (overvalued), and long the stocks for which FFWs decreased (undervalued).

Strategy utilizing FFW change

Note: We divided our universe of TSE-1 stocks into five groups on the basis of composite factor (TOPIX, R/N and Passive Fund Buy/Sell) at the beginning of each month. We then calculated the monthly return on a strategy combining long positions on the group of stocks with the lowest factor values (#1) and short positions on the group of stocks with the highest factor values (#5). Chart shows cumulative monthly return. We did not take transaction costs into account. Analysis is based on historical share prices and does not guarantee future performance. Sample period is January 2002 through April 2013.

Source: Nomura
We have seen more favorable investment environment in the Japanese equity market for profit-based factors to perform well.

We propose the following three investment ideas:

1. Strategy utilizing non-resident investors’ stock selection skills
2. Revision strategy in the phase when the ROE-P/B curve becomes steep
3. Contrarian strategies based on passive fund trading
## Appendix (1): definitions of factors

### Definitions of factors

<table>
<thead>
<tr>
<th>Factor</th>
<th>Factor definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1P/E</td>
<td>#1 (undervalued) - #5 (overvalued) Market cap / earnings forecast (next-FY forecast where available; IBES consensus forecast &gt; Toyo Keizai forecast)</td>
</tr>
<tr>
<td>P/B</td>
<td>#1 (undervalued) - #5 (overvalued) Market cap / actual shareholders’ equity</td>
</tr>
<tr>
<td>Dividend yield</td>
<td>#5 (high) - #1 (low) Calculated from Nikkei estimated dividends</td>
</tr>
<tr>
<td>ROE</td>
<td>#5 (high) - #1 (low) Earnings forecast / actual shareholders’ equity (next-FY forecast where available; IFIS consensus forecast &gt; Toyo Keizai forecast)</td>
</tr>
<tr>
<td>Profit margin</td>
<td>#5 (high) - #1 (low) Earnings forecast / sales forecast (next-FY forecast where available; IFIS consensus forecast &gt; Toyo Keizai forecast)</td>
</tr>
<tr>
<td>Sales turnover ratio</td>
<td>#5 (high) - #1 (low) Sales forecast / total assets (next-FY forecast where available; IFIS consensus forecast &gt; Toyo Keizai forecast)</td>
</tr>
<tr>
<td>High financial leverage</td>
<td>#5 (high) - #1 (low) Total assets / Net Equity</td>
</tr>
<tr>
<td>High revision</td>
<td>#5 (high) - #1 (low) Recurring profit forecast / past 3-month average recurring profit forecast – 1 (IFIS consensus forecast where available, otherwise Toyo Keizai forecast)</td>
</tr>
<tr>
<td>High volatility</td>
<td>#5 (high) - #1 (low) Standard deviation of daily share price return (past 60 days)</td>
</tr>
<tr>
<td>Large cap</td>
<td>#5 (large cap) - #1 (small cap) Log market cap</td>
</tr>
<tr>
<td>High default probability</td>
<td>#5 (high) - #1 (low) Estimated using Merton options theory</td>
</tr>
<tr>
<td>Historical 6-month return</td>
<td>#5 (high) - #1 (low)</td>
</tr>
<tr>
<td>Historical 3-month return</td>
<td>#5 (high) - #1 (low)</td>
</tr>
<tr>
<td>Herding</td>
<td>#5 (high) - #1 (low) * Active funds defined as all the active (long-only) funds in the Japanese equities category, as categorized by The Investment Trusts Association, Japan</td>
</tr>
<tr>
<td>Equity finance</td>
<td>#5 (high) - #1 (low) Change in no. of shares outstanding compared to 24 months previously</td>
</tr>
<tr>
<td>Earnings surprise (progress)</td>
<td>#5 (high) - #1 (low) Calculated from cumulative recurring profits (from Q1 through most recent quarter) as % of consensus recurring profit forecast (FY1)</td>
</tr>
<tr>
<td>Earnings surprise (share price response)</td>
<td>#5 (high) - #1 (low) Cumulative return versus TOPIX from most recent results announcement date to two trading days after announcement</td>
</tr>
<tr>
<td>Earnings surprise (company earnings estimate)</td>
<td>#5 (high) - #1 (low) Company estimate versus consensus recurring profit forecast (FY1) (IFIS consensus forecast &gt; Toyo Keizai forecast)</td>
</tr>
</tbody>
</table>

Source: Nomura
Appendix (2) performance of Japanese fundamental-based active funds

Average performance of Japanese fundamental-based active funds

End-2010/12 = 0% Cumulative return

Note: Shows average daily return (Jensen’s alpha), on an indexed basis, for all long-only active domestic publicly offered investment trusts (based on Investment Trusts Association, Japan categories). Sample period is January 2011 through 10 May 2013.

Source: Nomura
Appendix (3): transition in shareholding at market value by investor category

Transition in shareholding at market value by investor category

Note: All domestic stock exchanges (Tokyo, Osaka, Nagoya, Fukuoka and Sapporo) in Japan. The market value of public pension funds is not included in that of Annuity Trusts.

- Business corporations: All companies incorporated in Japan (ex “Financial institutions” and “Securities companies”).
- Individuals and others: Individuals and non-incorporated groups with Japanese nationality, regardless of their place of residence.
- Foreign corporations: Corporations that were established based on foreign laws; foreign and municipal governments, and entities that are not incorporated; and individuals whose nationalities are other than Japanese, regardless of their place of residence.
- Financial institutions
  > City, regional banks, etc.: Regular Japanese banks licensed under the Banking Act and the Long-Term Credit Bank Act (There have been no regular Japanese banks licensed under the Long-Term Credit Bank Act since the 2006 Shareownership Survey)
  > Trust banks: Trust banks that are members of the Trust Companies Association of Japan
  > Investment trusts: Trust assets of trustors that are stipulated in the Investment Trust Act (Act on Investment Trusts and Investment Corporations), and whose nominees (trustees) are banks that conduct trust business
  > Annuity trusts: Employees’ pension funds that are stipulated in the Employees’ Pension Insurance Act, and corporate pensions stipulated in the Defined-Benefit Corporate Pension Act or the Defined Contribution Pension Act, whose nominees (trustees) are banks that conduct trust business. (excluding public pensions under management)
  > Life insurance companies: Life insurance companies that are stipulated in the Insurance Business Act
  > Non-life insurance companies: Non-life insurance companies that are stipulated in the Insurance Business Act
  > Other financial institutions: Financial institutions other than those stipulated above, including credit unions (shinkin banks), credit associations, agriculture-related financial institutions, mutual aid associations, and government-related financial institutions, etc.

Source: Shareownership Survey (TSE), Nomura
## Appendix (4): outline regarding periodic review of FFW

### Outline of calculating FFW

<table>
<thead>
<tr>
<th>Outline</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>Estimate the amount of non-free-float shares using publicly available documents released by listed companies.</td>
</tr>
<tr>
<td>(2)</td>
<td>Calculate non-FFW. ((\text{Non-free-float shares} / \text{listed shares}))</td>
</tr>
<tr>
<td>(3)</td>
<td>Obtain the FFW by removing the non-free-float factor from 1. ((1 - \text{Non-FFW})) (\ast) TSE multiply the FFW by 0.75x for stocks recognized as having low liquidity and newly listed stocks</td>
</tr>
</tbody>
</table>

*Source: Nomura based on Tokyo Stock Exchange Index Guidebook published 9 February 2012*

### Definitions of free-float shares and non-free-float shares

#### Estimation of non-free-float shares

Shares held by the top 10 major shareholders, treasury stocks, shares held by the board of directors, and other shares TSE seems not available for trading in the market.

#### TSE may treat shares held by the top 10 major shareholders as free-float shares in the following case.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Major shareholder</th>
</tr>
</thead>
<tbody>
<tr>
<td>As a general rule, shares considered as free-float.</td>
<td>Securities finance companies, securities depositories, nominees for depository Receipts</td>
</tr>
</tbody>
</table>

**Shares likely to be seemed as free-float**

Cases where any of the following conditions are met and the TSE deems it appropriate to consider such shares as free-float.
- There are descriptions in the Securities Report on the type of trust, the purpose of purchase of shares, etc.
- It is clear that shares are held by several beneficiaries and managed centrally
- It is clear that shares are held for margin Transaction

*Source: Nomura based on Tokyo Stock Exchange Index Guidebook published 9 February 2012*

### Periodic Review

<table>
<thead>
<tr>
<th>Settlement Term</th>
<th>Announcement Date</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>January – March</td>
<td>Fifth business day of October</td>
<td>Last business day of October</td>
</tr>
<tr>
<td>April – June</td>
<td>Fifth business day of January</td>
<td>Last business day of January</td>
</tr>
<tr>
<td>July – September</td>
<td>Fifth business day of April</td>
<td>Last business day of April</td>
</tr>
<tr>
<td>October - December</td>
<td>Fifth business day of July</td>
<td>Last business day of July</td>
</tr>
</tbody>
</table>

*The TSE may review FFW in the cases (allocation of new shares to a third party, etc) where it seems that the existing FFW is expected to be significantly affected.*

*Source: Nomura based on Tokyo Stock Exchange Index Guidebook published 9 February 2012*
Appendix A-1

Any Authors named on this report are Research Analysts unless otherwise indicated

Analyst Certification

I, Akihiro Murakami, hereby certify (1) that the views expressed in this Research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of my compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

Important Disclosures

Online availability of research and conflict-of-interest disclosures

Nomura research is available on www.nomuranow.com/research, Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne.

Important disclosures may be read at http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email grpsupport@nomura.com for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm’s total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Nomura Global Financial Products Inc. (“NGFP”) Nomura Derivative Products Inc. (“NDPI”) and Nomura International plc. (“NIplc”) are registered with the Commodities Futures Trading Commission and the National Futures Association (NFA) as swap dealers. NGFP, NDPI, and NIplc are generally engaged in the trading of swaps and other derivative products, any of which may be the subject of this report.

Any authors named in this report are research analysts unless otherwise indicated. Industry Specialists identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have coverage. Industry Specialists do not contribute in any manner to the content of research reports in which their names appear. Marketing Analysts identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura’s Equity Research product in the sector for which they have coverage. Marketing Analysts may also contribute to research reports in which their names appear and publish research on their sector.
Disclaimers

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. The term "Nomura Group" used herein refers to Nomura Holdings, Inc. or any of its affiliates or subsidiaries and may refer to one or more Nomura Group companies including: Nomura Securities Co., Ltd. (‘NSC’) Tokyo, Japan; Nomura International plc (‘NIplc’), UK; Nomura Securities International, Inc. (‘NSI’), New York, US; Nomura International (Hong Kong) Ltd. (‘NIHK’), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. (‘NFIK’), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association (‘KOFIA’) can be found on the KOFIA Intranet at http://dis.kofia.or.kr); Nomura Singapore Ltd. (‘NSL’), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Nomura Australia Ltd. (‘NAL’), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission (‘ASIC’) and holder of an Australian financial services licence number 246412; P.T. Nomura Indonesia (‘PTNI’), Indonesia; Nomura Securities Malaysia Sdn. Bhd. (‘NSM’), Malaysia; NIHK, Taipei Branch (‘NITB’), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited (‘NFASL’), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivasagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, MCX: INE261299034) and NIplc, Madrid Branch (‘NIplc, Madrid’). ‘CNS Thailand’ next to an analyst’s name on the front page of a research report indicates that the analyst is employed by Capital Nomura Securities Public Company Limited (‘CNS’) to provide research assistance services to NSL under a Research Assistance Agreement. CNS is not a Nomura entity.

THIS MATERIAL IS: (I) FOR YOUR PRIVATE INFORMATION, AND WE ARE NOT SOLICITING ANY ACTION BASED UPON IT; (II) NOT TO BE CONSTRUED AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE ILLEGAL; AND (III) BASED UPON INFORMATION FROM SOURCES THAT WE CONSIDER RELIABLE, BUT HAS NOT BEEN INDEPENDENTLY VERIFIED BY NOMURA GROUP.

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information.

Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document. Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice.
Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor’s. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of MSCI Inc. (‘MSCI’). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates.

Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements. Clients outside of the US may access the Nomura Research Trading Ideas platform (Retina) at http://go.nomuranow.com/equities/tradingideas/retina/

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns.

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment. The securities described herein may not have been registered under the US Securities Act of 1933 (the ‘1933 Act’), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction.
This document has been approved for distribution in the UK and European Economic Area as investment research by NIplc. NIplc is authorised by the Prudential Regulation Authority ('PRA'), regulated by the Financial Conduct Authority and the PRA, and is a member of the London Stock Exchange. This document does not constitute a personal recommendation within the meaning of applicable regulations in the UK, or take into account the particular investment objectives, financial situations, or needs of individual investors. This document is intended only for investors who are 'eligible counterparties' or 'professional clients' for the purposes of applicable regulations in the UK, and may not, therefore, be redistributed to persons who are 'retail clients' for such purposes. This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934.

This document has not been approved for distribution to persons other than ‘Authorised Persons’, ‘Exempt Persons’ or ‘Institutions’ (as defined by the Capital Markets Authority) in the Kingdom of Saudi Arabia (‘Saudi Arabia’) or to clients other than ‘professional clients’ (as defined by the Dubai Financial Services Authority) in the United Arab Emirates (‘UAE’) by Nomura Saudi Arabia, NIplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or to any person other than ‘Authorised Persons’, ‘Exempt Persons’ or ‘Institutions’ located in Saudi Arabia or to clients other than ‘professional clients’ in the UAE. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are an ‘Authorised Person’, an ‘Exempt Person’ or an ‘Institution’ in Saudi Arabia or that you are a ‘professional client’ in the UAE and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the UAE or Saudi Arabia.

NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

Additional information is available upon request and disclosure information is available at the Nomura Disclosure web page:
Copyright © 2013 Nomura. All rights reserved.